Pre-Conference Review: ACR (American College of Rheumatology) Annual Meeting 2012.
The American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) 2012 Annual Meeting is being held in Washington, DC over November 9–14. In order to be prepared for this event Datamonitor has reviewed the abstracts and posters and discussed the conference with a prominent US rheumatologist, focusing on therapeutics for the rheumatoid arthritis indication.
Key points of interest:
Orencia SC pushes forward
Bristol-Myers Squibb is promoting the use of the subcutaneous formulation of Orencia, which is now available in the EU and US, with trials showing that an intravenous loading
dose is not necessary and positive 1-year data from AMPLE, the head-to-head study of Orencia verses Humira.
Actemra goes head to head
Although 24-week data from the ADACTA trial was presented at EULAR 2012, new 1- year data will continue to show positive results for Actemra, verses Humira. However,
look out for detail about Humira dose escalation in the presentation to understand how realistic to prescribing practice this is.
Tofacitinib data overload
With 14 abstracts at ACR/ARHP 2012, it is hard to miss the Pfizer marketing machine behind the “close to launch” JAK inhibitor tofacitinib. Data are very positive, and Pfizer
has selected the most impressive data to present, but given the continuing economic climate, price is still a key variable, and payors may not be convinced if the price is too
IL-17 not showing promise in rheumatoid arthritis
Some IL-17 data are being shown at ACR/ARHP 2012, including one particularly disappointing trial from Amgen’s brodalumab in rheumatoid arthritis. This could have an
impact on the validity of this as a target, but efficacy in the less biologic-crowded spondyloarthropathies does hold some promise.
Possible late breakers
Roche has previously promised more data at ACR/ARHP 2012, so we may see some late-breaker tocilizumab data.
Watch out for #ACR2012 on Twitter to get the latest social media opinions.